
|Articles|January 15, 2003
IOP-lowering efficacy of bimatoprost, latanoprost weighed
Bimatoprost 0.03% (Lumigan, Allergan) offers more efficacy than latanoprost 0.005% (Xalatan, Pharmacia) for lowering elevated IOP and is similarly well tolerated, according to the results of a 6-month, multicenter, randomized, double-masked study.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
STAAR Surgical terminates proposed acquisition by Alcon
2
FDA grants Breakthrough Therapy Designation to Oculis’ privosegtor for optic neuritis
3
Rates of retinal layer thinning predict visual field progression in glaucoma
4
FDA Clears IND application for GenEditBio’s GEB-101 in TGFBI corneal dystrophy
5












































